CFO Gordon Dunn to depart Quoin Pharmaceuticals; will continue until successor named

Quoin Pharmaceuticals, Ltd.

Mutual separation agreed on July 3, 2025; CFO Gordon Dunn to leave later this year.
Mr. Dunn will continue in his role until his successor is appointed.
Separation agreement anticipated; will be filed as an exhibit to a future Form 8-K or periodic report.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.